Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Visual-Spatial Dysfunction in Parkinson’s Disease: an Exploratory Multimodal Biomarker Study
Movement Disorders
P14 - Poster Session 14 (8:00 AM-9:00 AM)
3-002

To explore neural substrates of visual-spatial dysfunction in Parkinson’s Disease (PD).

In PD, abnormal ocular-motor function can affect visual exploration strategies, while restricted visuospatial processing may negatively influence motor function.

Cross-sectional analysis of 18 PD patients and 14 matched controls (HC). Ocular motor function was recorded by a binocular eye tracker (Eye Link-II) during the Benton Visual Recognition Test (BVRT). Visuospatial function was assessed by MoCA, Rey-Osterrieth Figure (RFT), and computerized tests (Navon Test, Visual Search, Visual Reaction). MDS-UPDRS, Pegboard Test and Timed Up and Go Test (TUG) assessed motor function. Patterns of functional connectivity (FC) on resting-state fMRI were investigated within the dorsal attention (DAN), executive control (ECN), fronto-occipital (FOC), primary and secondary visual networks, through independent component analysis. Partial correlations were performed with age and gender as covariates between clinical and FC outcomes. Variables showing a Pearson coefficient ≥ ±0.75 were considered significant.

PD subjects showed poorer performance on UPDRS-III (p<0.002), Pegboard Test (p<0.002), TUG (p<0.003), and Navon Test (number of errors, p<0.003) [table #1]. A trend towards worse scores in RFT was observed (p= 0.09). During BVRT, PD patients generated more saccades and longer path lenghts to complete the task [table #2]. PD patients exhibited higher FC levels within the DAN and ECN (p<0.001, adjusted for cluster size). In both groups performances on MoCA strongly correlated with FC in the DAN, FOC and ECN. In HC, performances on Navon Test correlated with FC in the FOC. In PD performances on TUG correlated with FC in the ECN.

Evidence of impaired ocular-motor exploration and altered cognitive processing of visual information was found in PD. These findings were accompanied by stronger FC in brain networks involved in top-down attentional control of perceptual information. These changes may reflect compensatory mechanisms boosting attentional resources to preserve motor-cognitive function in these patients.

Authors/Disclosures
Alberto Cucca, MD (The Marlene and Paolo Fresco Institute for Parkinsons and Movement Disorders)
PRESENTER
No disclosure on file
No disclosure on file
Mahya Beheshti, MBBS (The Mount Sinai Hospital) No disclosure on file
No disclosure on file
No disclosure on file
Kush Sharma, MBBS Dr. Sharma has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Alessandro Di Rocco, MD (Lenox Hill Hospital - Dept Neurology) Dr. Di Rocco has nothing to disclose.
Maria F. Ghilardi, MD No disclosure on file
Matilde Inglese, MD, PhD (University of Genoa) Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.
John-Ross Rizzo No disclosure on file
Milton Biagioni, MD (UCB Biopharma SRL) No disclosure on file
Andrew S. Feigin, MD (NYU Langone Health) Dr. Feigin has received personal compensation for serving as an employee of Rho, Inc.. Dr. Feigin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kenai. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ADCS/ATRI. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Feigin has received research support from Huntngton Study Group. The institution of Dr. Feigin has received research support from Prilenia.